Key facts
- It has raised $12.0M; the latest was Early Stage VC in Jul 2025.
- Notable investors include Partners Investment, Premier Partners, Bluepoint Partners, K2 Investment Partners, Hyosung Ventures — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Aigen Sciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Aigen Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aigen Sciences
Operator of an artificial intelligence (AI) based new drug development platform intended to discover high-potency drugs. The company's platform accelerates the development of therapies by combining scientific expertise with autonomous AI systems, enabling pharmaceutical researchers to get effective drugs and achieve higher success rates in clinical trials while reducing costs and improving efficiency.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2021
- Employees
- 9
- Website
- aigensciences.com/
- Ownership
- Privately Held (backing)
Aigen Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aigen Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aigen Sciences in its N-PORT filings yet. We sweep new filings monthly.